Fig. 2From: Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based studyPopulation-level health impact of routine and alternative strategies of vaccinating girls and women aged 12 through 26 years on 9-valent HPV-related anogenital warts and other non-cervical cancers. a Diagnosed anogenital warts among women (arrows spanning the curves represent the incremental benefit between strategies). b Diagnosed anogenital warts among men. c Diagnosed non-cervical cancer among women d Diagnosed cancer among men.GOV-4vHPV included routine vaccination of 12–16-year old girls with 4vHPV from 2021 onwards; GOV-9vHPV included routine vaccination of 12–16-year old girls with 9vHPV; GOV + Catch-Up-9vHPV consisted of routine vaccination of 12–16-year old girls from 2021 onwards and temporary catch-up vaccination of 17–26 years old girls and women with 9vHPV until 2025. All vaccination strategies were combined with cervical cancer screeningBack to article page